Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
bezafibrate nuclear receptor subfamily 1 group i member 2 small molecule NA drugbank Diabetes Mellitus[MeSHID:D003920]
Hypertriglyceridemia[MeSHID:D015228]
Disease[MeSHID:D004194]
Diet therapy[MeSHID:D004035]
Hyperlipidemia[MeSHID:D006949]
Arteriosclerosis[MeSHID:D001161]
Neoplasm Metastasis[MeSHID:D009362]
Atherosclerosis[MeSHID:D050197]
Weight decreased[MeSHID:D015431]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational partial agonist
bezafibrate peroxisome proliferator-activated receptor alpha small molecule Successful target TTD , drugbank , DGIDB Diabetes Mellitus[MeSHID:D003920]
Hypertriglyceridemia[MeSHID:D015228]
Disease[MeSHID:D004194]
Diet therapy[MeSHID:D004035]
Hyperlipidemia[MeSHID:D006949]
Arteriosclerosis[MeSHID:D001161]
Neoplasm Metastasis[MeSHID:D009362]
Atherosclerosis[MeSHID:D050197]
Weight decreased[MeSHID:D015431]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 5.79 approved,investigational agonist
bezafibrate peroxisome proliferator-activated receptor delta small molecule NA drugbank , DGIDB Diabetes Mellitus[MeSHID:D003920]
Hypertriglyceridemia[MeSHID:D015228]
Disease[MeSHID:D004194]
Diet therapy[MeSHID:D004035]
Hyperlipidemia[MeSHID:D006949]
Arteriosclerosis[MeSHID:D001161]
Neoplasm Metastasis[MeSHID:D009362]
Atherosclerosis[MeSHID:D050197]
Weight decreased[MeSHID:D015431]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 0.49 approved,investigational agonist
bezafibrate peroxisome proliferator-activated receptor gamma small molecule NA drugbank Diabetes Mellitus[MeSHID:D003920]
Hypertriglyceridemia[MeSHID:D015228]
Disease[MeSHID:D004194]
Diet therapy[MeSHID:D004035]
Hyperlipidemia[MeSHID:D006949]
Arteriosclerosis[MeSHID:D001161]
Neoplasm Metastasis[MeSHID:D009362]
Atherosclerosis[MeSHID:D050197]
Weight decreased[MeSHID:D015431]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational agonist
bezafibrate retinoic acid receptor rxr-alpha small molecule NA drugbank Diabetes Mellitus[MeSHID:D003920]
Hypertriglyceridemia[MeSHID:D015228]
Disease[MeSHID:D004194]
Diet therapy[MeSHID:D004035]
Hyperlipidemia[MeSHID:D006949]
Arteriosclerosis[MeSHID:D001161]
Neoplasm Metastasis[MeSHID:D009362]
Atherosclerosis[MeSHID:D050197]
Weight decreased[MeSHID:D015431]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational agonist
bezafibrate retinoic acid receptor rxr-beta small molecule NA drugbank Diabetes Mellitus[MeSHID:D003920]
Hypertriglyceridemia[MeSHID:D015228]
Disease[MeSHID:D004194]
Diet therapy[MeSHID:D004035]
Hyperlipidemia[MeSHID:D006949]
Arteriosclerosis[MeSHID:D001161]
Neoplasm Metastasis[MeSHID:D009362]
Atherosclerosis[MeSHID:D050197]
Weight decreased[MeSHID:D015431]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational agonist
bezafibrate retinoic acid receptor rxr-gamma small molecule NA drugbank Diabetes Mellitus[MeSHID:D003920]
Hypertriglyceridemia[MeSHID:D015228]
Disease[MeSHID:D004194]
Diet therapy[MeSHID:D004035]
Hyperlipidemia[MeSHID:D006949]
Arteriosclerosis[MeSHID:D001161]
Neoplasm Metastasis[MeSHID:D009362]
Atherosclerosis[MeSHID:D050197]
Weight decreased[MeSHID:D015431]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational agonist
click here to return to the previous page